-
R172598-100mgDual cdk4/cdk6 inhibitor.
-
R172598-10mgDual cdk4/cdk6 inhibitor.
-
R172598-1gDual cdk4/cdk6 inhibitor.
-
R172598-250mgDual cdk4/cdk6 inhibitor.
-
R172598-25mgDual cdk4/cdk6 inhibitor.
-
R172598-50mgDual cdk4/cdk6 inhibitor.
-
R172598-5mgDual cdk4/cdk6 inhibitor.
-
R125138-10mgRivaroxaban is an oral, direct inhibitor of Factor X, being developed for the prevention and treatment of arterial and venous thrombosis with a Ki of 0.4 nM. Rivaroxaban also inhibits prothrombinase activity (IC50 = 2.1 nM). Rivaroxaban also shows a
-
R125138-1gRivaroxaban is an oral, direct inhibitor of Factor X, being developed for the prevention and treatment of arterial and venous thrombosis with a Ki of 0.4 nM. Rivaroxaban also inhibits prothrombinase activity (IC50 = 2.1 nM). Rivaroxaban also shows a
-
R125138-250mgRivaroxaban is an oral, direct inhibitor of Factor X, being developed for the prevention and treatment of arterial and venous thrombosis with a Ki of 0.4 nM. Rivaroxaban also inhibits prothrombinase activity (IC50 = 2.1 nM). Rivaroxaban also shows a
-
R125138-25gRivaroxaban is an oral, direct inhibitor of Factor X, being developed for the prevention and treatment of arterial and venous thrombosis with a Ki of 0.4 nM. Rivaroxaban also inhibits prothrombinase activity (IC50 = 2.1 nM). Rivaroxaban also shows a
-
R125138-50mgRivaroxaban is an oral, direct inhibitor of Factor X, being developed for the prevention and treatment of arterial and venous thrombosis with a Ki of 0.4 nM. Rivaroxaban also inhibits prothrombinase activity (IC50 = 2.1 nM). Rivaroxaban also shows a